ILEVRO
Peaknepafenac
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Clinical Trials (5)
Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%
Started Apr 2016
200 enrolled
Cataract
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
Started Oct 2013
57 enrolled
Treatment of Ocular Inflammation Associated With Cataract Surgery
Nepafenac Once Daily for Macular Edema - Study 2
Started Jun 2013
819 enrolled
Non-Proliferative Diabetic RetinopathyCataract
Nepafenac Once Daily for Macular Edema - Study 1
Started Jun 2013
881 enrolled
Non-Proliferative Diabetic RetinopathyCataract
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Started Apr 2013
50 enrolled
CataractRetinal EdemaInflammation
Loss of Exclusivity
LOE Date
Mar 31, 2032
73 months away
Patent Expiry
Mar 31, 2032